When it comes to weight loss drugs, Ozempic has become a phenomenon. With nearly $14 billion in sales in 2023, it shows no ...

Canadian public and private insurers have balked at covering certain medication for weight-loss, but that might change as the ...

Novo Holdings plans to double its newly acquired contract drugmaker, Catalent, within five years, focusing on U.S. manufacturing. The $16.5 billion acquisition is aimed at enhancing supply chains amid ...

President-elect Trump’s threat to tariff Denmark if it resists his acquisition plans for the island territory of Greenland ...

According to Wegovy’s manufacturer, the drug could cost as little as $0 with insurance, or up to $650 for a 28-day supply without insurance. Your cost may vary depending on other factors ...

I'm cautious about Novo Nordisk's short-term prospects due to the recent selloff, but see long-term potential with high ...

Lilly achieved the supply milestone first ... had been in shortage—the 0.25-mg starter dose of its obesity GLP-1 Wegovy—as available in late October. At the time, the company said it was ...

Semaglutide, the active ingredient in Ozempic and Wegovy, was also included on the list. The FDA is prioritizing the review ...

the chemical name for Wegovy, and said the agency should consider their role in alleviating the obesity drug supply crunch. Another industry group that represents larger compounding pharmacies ...

Denmark is home to drugmaker Novo Nordisk, the maker of highly sought GLP-1 drugs Ozempic and Wegovy, which are approved ... leading to supply chain disruptions and potential price increases.

According to NovoCare, Wegovy’s manufacturer, people with private or commercial insurance can pay as little as $0 per 28-day supply of the medication. People without insurance can expect to pay ...